Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.


== Anti-cancer mechanism ==
See Insulin-like growth factor 1 receptor role in cancer.


== Clinical trials ==
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths but others continued.It was to have been included in the I-SPY2 breast cancer trial.


== References ==